Well-established methods include positron emission tomography (PET)-based brain function imaging and cerebrospinal fluid (CSF) analysis, which detects deposition of AD biomarkers such as amyloid-β and tau proteins in the brain9,10. Here, MAPT is linked to Alzheimer disease.